drugset / Trial / NCT02644473

Safety of Topical Tranexamic Acid in Total Joint Arthroplasty in High Risk Patients

NCT02644473 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate whether there is a difference in symptomatic thromboembolism events in the subset of patients with a history of, or risk factors for thromboembolic disease for topically applied tranexamic acid in total joint arthroplasty.

Timeline

Start
2016-02
Primary completion
2019-01
Completion
2019-01

Outcome

Outcome not reported

Stopped: “Study did not receive IRB approval, so did not start”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1.5 g Topical